<SEC-DOCUMENT>0001104659-23-002378.txt : 20230328
<SEC-HEADER>0001104659-23-002378.hdr.sgml : 20230328
<ACCEPTANCE-DATETIME>20230109201100
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-23-002378
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JATT Acquisition Corp
		CENTRAL INDEX KEY:			0001855644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		4225 EXECUTIVE SQUARE
		STREET 2:		SUITE 600
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-247-0520

	MAIL ADDRESS:	
		STREET 1:		4225 EXECUTIVE SQUARE
		STREET 2:		SUITE 600
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	JATT Acquisition Corp
		DATE OF NAME CHANGE:	20210407
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify"><IMG SRC="tm2218919d19_correspimg001.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: left; width: 26%; vertical-align: middle">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Giovanni
    Caruso</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Partner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">345 Park Avenue<BR>
    New York, NY 10154</P></TD>
    <TD STYLE="width: 26%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Direct&#8239;&#8239;&#8239;&#8239;</B>212.407.4866<BR>
<B>Main&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>212.407.4000<BR>
<B>Fax</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;212.937.3943<BR>
gcaruso@loeb.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Via Edgar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">January 9, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Office of Life Sciences<BR> U.S. Securities &amp; Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">100 F Street, NE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Washington, D.C. 20549</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: Mr. Conlon Danberg and Ms. Celeste
Murphy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in">Re:</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">JATT Acquisition Corp</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Amendment No. 3 to Registration Statement on Form S-4 Filed on <BR> December 15, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">File No. 333-267005</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.75pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Danberg and Ms. Murphy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On behalf of our client, JATT Acquisition Corp
(the &ldquo;<B>Company</B>&rdquo;), we hereby provide a response to the comments issued in a letter dated December 27, 2022 (the &ldquo;Staff&rsquo;s
Letter&rdquo;) regarding the Company&rsquo;s Amendment No. 3 to the Registration Statement on Form S-4 that was submitted on December
15, 2022 (the &ldquo;<B>Amendment No. 3</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">Concurrently
with the submission of this response letter, we are filing, through EDGAR, Amendment No. 4&nbsp;to the Registration Statement (&ldquo;<B>Amendment
No.&nbsp;4</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In order to facilitate the review by the staff
of the Securities and Exchange Commission (the &ldquo;<B>Staff&rdquo;</B>) of Amendment No. 4, we have responded, on behalf of the Company,
to the comments set forth in the Staff&rsquo;s Letter on a point-by-point basis. The numbered paragraphs set forth below respond to the
Staff&rsquo;s comments and correspond to the numbered paragraph in the Staff&rsquo;s Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 0"><B><U>Amendment No. 3 to Registration Statement on Form
S-4 filed December 15, 2022</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.8pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.8pt 0pt 0"><B><U>Summary of the Proxy Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 187.5pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 187.5pt 0pt 0"><B><U>The Parties to the Business Combination Zura, page
24</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 187.5pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">1.</TD><TD STYLE="text-align: left; padding-right: 9.55pt"><FONT STYLE="font-size: 10pt"><B>We note your revised disclosure regarding Zura and re-issue comment
7 from our August 3, 2022 letter in part. Please balance your disclosure regarding Zura to:</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.25pt"></TD><TD STYLE="width: 19.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>state that Zura was recently formed on January 18, 2022 and that it has not conducted any clinical tests itself, nor have any clinical tests
been conducted during the period since its inception;</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.25pt"></TD><TD STYLE="width: 19.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>state that Zura does not have any product candidates approved for sale and has not generated any revenue from product sales to date;</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.25pt"></TD><TD STYLE="width: 19.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 11.05pt"><FONT STYLE="font-size: 10pt"><B>note that the completed Phase 2 trial for torudokimab was conducted
in patients with atopic dermatitis and that following an interim analysis of the study, the sponsor determined that the efficacy data
observed did not warrant continuation of the trial and the study was terminated; and</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.25pt"></TD><TD STYLE="width: 19.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 9.35pt"><FONT STYLE="font-size: 10pt"><B>provide the current status of the planned randomized phase 2 studies
with torudokimab and ZB-168, including whether Zura has made an IND submission with the FDA for such studies.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 40.5pt"><FONT STYLE="background-color: white"><U>Response</U>:
We acknowledge the Staff&rsquo;s comment and have revised the disclosures on page 26.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt"><B>Additionally, we note your statement on page 228 that
asthma is &quot;[y]our lead indication&quot; and that your planned randomized Phase 2 studies &quot;will include asthma and may include
additional autoimmune indications.&quot; Please revise your summary description of Zura to indicate that asthma is your lead indication.
In this regard, we note that the current disclosure states that your planned Phase 2 studies &quot;may include asthma&quot; among other
indications.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt"><FONT STYLE="background-color: white"><U>Response</U>: We
acknowledge the Staff&rsquo;s comment and have revised the disclosures on page 228 and following to remove the reference to asthma as the &ldquo;lead indication.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Our Vision and Our Strategy, page 190&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">2.</TD><TD STYLE="padding-right: 10.5pt"><FONT STYLE="font-size: 10pt"><B>We note your statement that you are &quot;among the leaders in exploring
the therapeutic benefit of blocking IL33 with torudokimab, which has the potential to be a best in class mechanism based on the head to
head potency of torudokimab vs other IL33 inhibitors in vitro.&quot; Please expand on this statement to discuss the details of any head
to head comparisons of torudokimab vs other IL33 inhibitors that have been completed to date.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt"><FONT STYLE="background-color: white"><U>Response</U>: We
acknowledge the Staff&rsquo;s comment and have revised the disclosures on page 207.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Clinical trial Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 273.05pt 0pt 0"><B><U>Phase 1a single ascending dose trial Safety and
Tolerability, page 199</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 273.05pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">3.</TD><TD STYLE="padding-right: 5.25pt"><FONT STYLE="font-size: 10pt"><B>We refer to your statement that &quot;[o]verall, single and multiple
doses of torudokimab were safe and well tolerated by all subjects&quot; and reissue comment 28 from our August 3, 2022 letter. Determinations
with respect to safety and efficacy are within the sole authority of the FDA, EMA or equivalent foreign regulator. Please revise your
registration statement to remove the reference to doses of torudokimab being &quot;safe&quot; as well as any other statements relating
to safety and efficacy in instances where you have not yet received full approval for your product candidates</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="background-color: white"><U>Response</U>:
We acknowledge the Staff&rsquo;s comment and have revised the disclosures on page  215 and elsewhere to remove references to torudokimab as &ldquo;safe.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 177.95pt 0pt 0"><B><U>Certain Relationships and Related Party Transactions
of Zura Put-Call Letter Agreement, page 295</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 177.95pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">4.</TD><TD STYLE="padding-right: 9.85pt"><FONT STYLE="font-size: 10pt"><B>We note your description of the Put-Call Letter Agreement entered into
on December 8, 2022. Please revise this description to include the name of the investor and the number of shares subject to the agreement.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.8pt"><FONT STYLE="background-color: white"><U>Response</U>:
We acknowledge the Staff&rsquo;s comment and have revised the disclosures on page 311.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.8pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">5.</TD><TD STYLE="padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><B>We note your revised disclosure regarding the January 16, 2023 Outside
Date to consummate a business combination. It appears that you have also filed a proxy statement for an extraordinary general meeting
of shareholders to be held on January 12, 2023 to seek shareholder approval of an extension of the Outside Date from January 16, 2023
to April 17, 2023. In your next amendment, please include disclosure regarding this meeting and reflect any associated events such as
redemptions that may occur in connection with the extension amendment.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.5pt"><FONT STYLE="background-color: white"><U>Response</U>:
We acknowledge the Staff&rsquo;s comment and have added the disclosures on pages 9 and 37 of Amendment No.&nbsp;4. We further confirm
that the Company will make additional appropriate revisions to the Registration Statement once the amount of public share redemptions
are determined in connection with the Extraordinary General Meeting being held on January 12, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 47.5pt 0pt 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please call me at (212) 407-4866 if you would
like additional information with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Giovanni Caruso</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Giovanni Caruso</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2218919d19_correspimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2218919d19_correspimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ ) # 2(  A$! Q$!_\0
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ME.UC_MC_ .B4KBJ]JE2@X)M+8\>I4FIM)O<[7_A;7CC_ *#?_DI#_P#$4?\
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M('? [>@%;WBB/P!XG\1W6L2^,)K=KC9F);"1@-J!>NWVS^-0_P#"BO%'_/\
MZ/\ ]_I?_C='_"B?$_\ S_Z/_P!_I/\ XW1S4M.6=K!RU=;QO<S'\._#X1L4
M\;7#, =J_P!G2#)].E7=+OO"FJ_#;3]"UC77TZXM[M[@[;623KN ' Q_%GK4
MW_"B?$__ #_:/_W]D_\ C='_  HGQ1_S_P"D?]_I?_C=#E3:UJ?U]P*-1;0,
MW_A'/AYU_P"$XN/I_9TG^%0^*-<T&W\+6GA?PU)-/:I.;FZNID*&:3&!QUQC
MV'05L?\ "BO$_P#S_:/_ -_I?_C='_"BO%'_ #_Z/_W^E_\ C=-3I73E._\
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1O"HQ%:G*FTF:4*4XU$VC_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
